ClinicalTrials.gg
CompletedNCT02105974Updated Jan 24, 2018Results posted

Study Evaluating the Efficacy and Safety of Fluticasone Furoate/Vilanterol Inhalation Powder (FF/VI) Compared With Vilanterol Inhalation Powder (VI) in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

A Phase 3 interventional study of Fluticasone Furoate/Vilanterol and Vilanterol in Pulmonary Disease, Chronic Obstructive, sponsored by GlaxoSmithKline. Completed at 238 sites in 11 countries. Open to participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2018-01-24.

Sponsored by GlaxoSmithKline · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,621
Allocation
Randomized
Ages
40 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 25 studies testing fluticasone furoate in Pulmonary Disease, Chronic Obstructive — 2 open to participants now, 2 under way, none of them phase 3. fluticasone furoate · Pulmonary Disease, Chronic Obstructive.

Enrollment
4th of 25
1,621 · median 229
Started
2014
with 3 others
Phase 3
7 of 25
none open now
Registered
9th of 25
by date
Lead sponsor
21 of 25
GlaxoSmithKline

Among the 25 studies testing fluticasone furoate in Pulmonary Disease, Chronic Obstructive, this one is the 4th largest by enrollment, is one of 4 that started in 2014, is one of 7 in phase 3, and was the 9th registered.

Pulmonary Disease, Chronic Obstructive

5,523 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 856 are open to participants now.

Browse Pulmonary Disease, Chronic Obstructive studies →

Open to participants now

2 of the 25 studies testing fluticasone furoate in Pulmonary Disease, Chronic Obstructive are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About fluticasone furoate

fluticasone furoate: first FDA approval 2007 (FLONASE SENSIMIST ALLERGY RELIEF), first EMA approval 2008. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 558 Pulmonary Disease, Chronic Obstructive studies recruiting now, 307 (55%) set no upper age limit and 82 (15%) stop at 75 or younger; 29 take children under 18; 88 take healthy volunteers.

This study: 40 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 25 studies testing fluticasone furoate in Pulmonary Disease, Chronic Obstructive, or all of them as a file.
02

Study summary

This is a Phase IIIa, multicenter, randomized, stratified (reversibility status), double-blind, parallel-group study to evaluate the efficacy and safety of FF/VI 100/25 micrograms (mcg) once daily (QD) compared with VI 25 mcg QD, administered in the morning via the ELLIPTA™ inhaler. The primary objective of this study is to evaluate the contribution on lung function (as measured by trough forced expiratory volume in one second [FEV1]) of FF 100 mcg to the FF/VI 100/25 mcg QD combination by comparison of the latter with VI 25 mcg QD and the safety of FF/VI 100/25 mcg over a 12-week treatment period in subjects with COPD. ELLIPTA™ is a registered trademark of GlaxoSmithKline.

03

Conditions studied

  • Pulmonary Disease, Chronic Obstructive

Keywords

  • COPD
  • Fluticasone Furoate (FF)
  • Vilanterol (VI)
  • Dry Powder Inhaler
04

Who can participate

Ages eligible
40 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Type of subject: Outpatient
  • : Subjects must give their signed and dated written informed consent to participate
  • Gender: Male subjects or female subjects. Female subjects must be or using a highly effective method for avoidance of pregnancy. The decision to include or exclude women of may be made at the discretion of the investigator in accordance with local practice in relation to adequate .
  • Age: >=40 years of age at Screening (Visit 1)
  • diagnosis: Subjects with a clinical history of COPD in accordance with the definition by the American Thoracic Society/European Respiratory Society: COPD is a preventable and treatable disease characterized by airflow limitation that is not fully reversible. The airflow limitation is usually progressive and is associated with an abnormal inflammatory response of the lungs to noxious particles or gases, primarily caused by cigarette smoking. Although COPD affects the lungs, it is also associated with significant systemic consequences.
  • Severity of disease: Subjects with a measured post-albuterol (salbutamol) / Forced Vital Capacity (FVC) ratio of \<=0.70 and FEV1 >=30 to \<=70 percent of predicted normal values using Global Lung Function Initiative 2012 reference equations at Screening (Visit 1).
  • Tobacco use: Subjects with a current or prior history of >=10 pack-years of cigarette smoking at Screening (Visit 1). Former smokers are defined as those who have stopped smoking for at least 6 months prior to Visit 1.
  • History of COPD exacerbation: A documented history (e.g., medical record verification) of at least one COPD exacerbation in the 12 months prior to Screening (Visit 1) that required either systemic/oral , antibiotics and/or hospitalization.
  • Current symptoms of COPD: A Subject Diary combined symptom score (combination of breathlessness, cough, sputum, and night time awakenings requiring treatment with albuterol [salbutamol]) of >=4 on at least 5 of the 7 days immediately preceding Visit 2 (Randomization)
  • Criteria: QTc \<450 msec or QTc \<480 msec for patients with bundle branch block.

Exclusion criteria

Exclusion Criteria:

  • Pregnancy: Women who are pregnant or lactating or are planning on becoming pregnant during the study.
  • Asthma: Subjects with a current diagnosis of asthma. (Subjects with a prior history of asthma are eligible if they have a current diagnosis of ).
  • Other respiratory disorders: Subjects with alpha1-antitrypsin deficiency as the underlying cause of COPD as the underlying cause of COPD, active tuberculosis, lung cancer, bronchiectasis (Note: focal bronchiectasis is not exclusionary), sarcoidosis, pulmonary fibrosis (Note: focal fibrotic pulmonary lesions are not exclusionary), primary pulmonary hypertension, interstitial lung diseases, or other active pulmonary diseases.
  • Lung resection: Subjects with lung volume reduction surgery within the 12 months prior to Screening (Visit 1).
  • Chest X-ray (or computed tomography [CT] scan): Subjects with a chest X-ray (or CT scan) that reveals evidence of abnormalities not believed to be due to the presence of COPD. A chest X-ray must be taken at Screening (Visit 1) if a chest X-ray or CT scan is not available within 1 year prior to Screening (Visit 1).
  • Hospitalization: Subjects who are hospitalized due to poorly controlled COPD that has not resolved at least 4 weeks prior to Screening (Visit 1) and at least 6 weeks following the last dose of systemic .
  • Poorly controlled COPD: Subjects with poorly controlled COPD, defined as the occurrence of any of the following in the 6 weeks prior to Screening (Visit 1): Acute worsening of COPD that is managed by subject with systemic corticosteroids or antibiotics or that requires treatment prescribed by a physician.
  • Lower respiratory tract infection: Subjects with lower respiratory tract infection that required the use of antibiotics within 6 weeks prior to Screening (Visit 1).
  • COPD exacerbation/lower respiratory tract infection during the Run-In Period: Subjects who experience a moderate/severe COPD exacerbation (As per definition of "COPD Exacerbations and Pneumonia" in protocol) and/or a lower respiratory tract infection (including pneumonia) during the Run-In Period.
  • Abnormal, clinically significant laboratory finding: Subjects who have an abnormal clinical significant finding in any liver chemistry test at Screening (Visit 1) or upon repeat prior to randomization.
  • Abnormal, clinically significant 12-lead at Screening (Visit 1): Subjects who have an abnormal, clinically significant 12-Lead electrocardiogram (ECG) finding at Screening (Visit 1) or upon repeat prior to randomization.
  • Other diseases/abnormalities: Subjects with historical or current evidence of clinically significant and unstable disease such as cardiovascular (e.g., patients requiring implantable cardioverter-defibrillators (ICD), pacemaker requiring a rate set >60 beats per minute (bpm), uncontrolled hypertension, New Your Heart Association Class IV, known \<30 percent) neurological, psychiatric, renal, hepatic, immunological, endocrine (including uncontrolled diabetes or thyroid disease), peptic ulcer disease, or hematological abnormalities.
  • Liver disease: Subjects who have unstable liver disease (as defined by the presence of ascites, encephalopathy, coagulopathy, hypoalbuminaemia, oesophageal or gastric varices or persistent jaundice), cirrhosis, known biliary abnormalities (with the exception of Gilbert's syndrome or asymptomatic gallstones). Note: Subjects with chronic stable and C are eligible if the subject otherwise meets entry criteria (e.g., presence of hepatitis B surface antigen or positive test result within 3 months of screening). However, subjects with chronic stable hepatitis B are excluded if significant or cytotoxic agents are administered, due to risk of hepatitis B reactivation, unless the hepatitis B antivirals are administered as outlined in the Chronic Hepatitis B American Association for the Study of Liver Diseases' (AASLD) Practice Guidelines.
  • Cancer: Subjects with carcinoma that has not been in complete remission for at least 5 years. Carcinoma in situ of the cervix, squamous cell carcinoma and basal cell carcinoma of the skin would not be excluded if the subject has been considered cured within 5 years since diagnosis.
  • : Subjects with a history of allergy or to any of the study medications (e.g. beta-agonists, corticosteroids) or components of the inhalation powder (e.g., lactose, magnesium stearate). In addition, subjects with a history of severe milk protein allergy that, in the opinion of the investigator, contraindicates the subject's participation will also be excluded.
  • Drug/alcohol abuse: Subjects with a known or suspected history of alcohol or drug abuse within the last 2 years
  • Medication prior to spirometry: Subjects who are medically unable to withhold their albuterol (salbutamol) or their ipratropium bromide for the 4-hour period required prior to spirometry testing at each study visit.
  • Additional medication: Use of certain medications such as bronchodilators and corticosteroids for the protocol-specific times prior to Visit 1 (the Investigator will discuss the specific medications)"
  • Oxygen therapy: Subjects receiving treatment with long-term oxygen therapy (LTOT) or nocturnal oxygen therapy required for greater than 12 hours a day. Oxygen as needed (prn) use (i.e., \<=12 hours per day) is not exclusionary.
  • Sleep apnea: Subjects with clinically significant sleep apnea who require use of continuous positive airway pressure (CPAP) device or non-invasive positive pressure ventilation (NIPPV).
  • Pulmonary rehabilitation: Subjects who have participated in the acute phase of a Pulmonary Rehabilitation Program within 4 weeks prior to Screening (Visit 1) or who will enter the acute phase of a Pulmonary Rehabilitation Program during the study. Subjects who are in the maintenance phase of a Pulmonary Rehabilitation Program are not excluded.
  • Non-Compliance during Run-In Period: Failure to demonstrate adequate compliance defined as completion of Diary Card (completed all diary entries on at least 5 of the last 7 consecutive days), the ability to withhold anti-COPD medications and to keep clinic visit appointments. In addition, subjects must have recorded the Run-In study medication use on at least 5 of the last 7, consecutive days of the Run-In period to continue in the study.
  • Potential of non-compliance: Subjects at risk of non-compliance, or unable to comply with the study procedures. Any infirmity, disability, or geographic location that would limit compliance for scheduled visits.
  • Questionable validity of consent: Subjects with a history of psychiatric disease, intellectual deficiency, poor motivation or other conditions that will limit the validity of to participate in the study.
  • Prior use of study medication/other drugs: Subjects who have received an investigational drug within 30 days of entry into this study (Screening), or within 5 drug half-lives of the investigational drug, whichever is longer. Note: Subjects who participated in a previously completed study and/or were excluded/ withdrawn from an ongoing study that included/includes FF/VI and/or VI are eligible to participate in the current study, if they have not received investigational study medication within 30 days of Screening (Visit 1).
  • Affiliation with investigator site: Study investigators, sub-investigators, study coordinators, employees of a participating investigator or immediate family members of the aforementioned are excluded from participating in this study.
Terms in these criteria, in plain language(17)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
1,621 participants (actual)

Study arms

  • Experimental
    Fluticasone Furoate/Vilanterol 100/25 Inhalation Powder

    Inhaled corticosteroid (ICS)/long-acting beta2-agonist (LABA)

    Drug: Fluticasone Furoate/Vilanterol

  • Experimental
    Vilanterol 25 Inhalation Powder

    Long-acting beta2-agonist (LABA)

    Drug: Vilanterol

Interventions

  • DrugFluticasone Furoate/Vilanterol

    Drug pages: Fluticasone furoate · Vilanterol

    100 mcg FF micronized drug blended with lactose per blister in one strip and 25 mcg VI micronized drug blended with lactose and magnesium stearate per blister in another strip, administered together by ELLIPTA™ inhaler

  • 25 mcg of Vilanterol micronized drug (as the 'M' salt triphenylacetate) blended with lactose and magnesium stearate per blister in one strip and lactose in another strip, administered together by ELLIPTA™ inhaler

06

What researchers measure

Primary outcomes

  1. Mean Change From Baseline (BL) in Clinic Visit Trough (Pre-bronchodilator and Pre-dose) FEV1, on Treatment Day 84

    Pulmonary function was measured by forced expiratory volume in one second (FEV1), defined as the maximal amount of air that can be forcefully exhaled from the lungs in one second. Trough FEV1 measurements were taken electronically by spirometry on Days 2, 14, 28, 56 and 84. BL was defined as the mean of the assessments made 30 minutes pre-dose and immediately pre-dose on Treatment Day 1.Trough FEV1 was defined as the mean of the FEV1 values obtained 23 and 24 hours after previous morning's dosing. Change from BL was calculated as the average at each visit minus the BL value. Analysis was performed using a repeated measures model with covariates of treatment, reversibility status (stratum), BL, region, day, day by BL and day by treatment interactions.

    Time frame: Baseline to Day 84

Secondary outcomes

  1. Percentage of Rescue-free 24-hour Periods Over the Entire 12-week Treatment Period

    Participants were given daily record cards for daily completion from BL (Week -1) through Week 12 (Visit 7) each morning and prior prior to taking study medication (i.e., single-blind and double-blind study medication), supplemental medication (albuterol \[salbutamol\] if received). Participants recorded number of occasions supplemental albuterol/salbutamol (MDI and/or nebules) or oxitropium bromide (applicable sites in Japan) used over the previous 24 hours and any medical problems that they had experienced and any medication used to treat these medical problems over the previous 24 hours. Rescue-free 24-hour periods are defined as the 24-hour periods in which the rescue medication (albuterol \[salbutamol\]) was not used. The percentage of 24-hour periods are summarized for the entire treatment period (12 weeks). Analysis was performed using an analysis of covariance (ANCOVA) model with covariates of treatment, reversibility status (stratum), baseline (week -1) and region.

    Time frame: BL (Week -1), Week 1 to Week 12

  2. Time to First On-treatment Occurrence of Moderate or Severe COPD Exacerbation

    Time to first on-treatment exacerbation was analysed using a Cox proportional hazards model with terms for treatment, reversibility status and percent predicted FEV1 at screening. Exacerbation of COPD is defined by a worsening of symptoms requiring additional treatment. Moderate COPD exacerbation is worsening symptoms of COPD that require treatment with antibiotics and/or systemic corticosteroids. Severe COPD exacerbation is worsening symptoms of COPD that require treatment with in-patient hospitalization. The number of participants with On-Treatment moderate or severe COPD exacerbations are presented.

    Time frame: From the start of double blind study medication until visit 7 (week 12)/Early withdrawal

07

Results

Posted Apr 13, 2016

Participant flow

Par meeting continuation criteria during the run-in period were randomized (1:1) to receive fluticasone furoate (FF)/vilanterol (VI) or VI. Of the 2423 par screened, 1622 were randomized. 1620 received at least one dose of double-blind study medication and comprised the Intent-to-Treat population.

2 Week Run-in Period
Participant flow — 2 Week Run-in Period
MilestonePlacebo Run-InFF/VI 100/25 µg QDVI 25 µg QD
Started242300
Completed162200
Not completed80100
Withdrew: Withdrew during pre-screen period15800
Withdrew: Did not meet inclusion/exclusion criteri60300
Withdrew: Adverse event600
Withdrew: Study closed/terminated100
Withdrew: Lost to follow-up200
Withdrew: Withdrew consent2300
Withdrew: Investigator discretion800
12 Week (Wk) Treatment Period (TP)
Participant flow — 12 Week (Wk) Treatment Period (TP)
MilestonePlacebo Run-InFF/VI 100/25 µg QDVI 25 µg QD
Started0806814
Completed the treatment(trt) period0764754
Completed0764756
Not completed04258
Withdrew: Adverse event01418
Withdrew: Lack of efficacy069
Withdrew: Protocol deviation026
Withdrew: Participant reached stopping criteria012
Withdrew: Lost to follow-up001
Withdrew: Physician decision074
Withdrew: Withdrawal by subject01218

Outcome measures

PrimaryMean Change From Baseline (BL) in Clinic Visit Trough (Pre-bronchodilator and Pre-dose) FEV1, on Treatment Day 84

Pulmonary function was measured by forced expiratory volume in one second (FEV1), defined as the maximal amount of air that can be forcefully exhaled from the lungs in one second. Trough FEV1 measurements were taken electronically by spirometry on Days 2, 14, 28, 56 and 84. BL was defined as the mean of the assessments made 30 minutes pre-dose and immediately pre-dose on Treatment Day 1.Trough FEV1 was defined as the mean of the FEV1 values obtained 23 and 24 hours after previous morning's dosing. Change from BL was calculated as the average at each visit minus the BL value. Analysis was performed using a repeated measures model with covariates of treatment, reversibility status (stratum), BL, region, day, day by BL and day by treatment interactions.

Time frame:
Baseline to Day 84
Reported as:
Least squares mean · Liter
Mean Change From Baseline (BL) in Clinic Visit Trough (Pre-bronchodilator and Pre-dose) FEV1, on Treatment Day 84
LiterFF/VI 100/25 µg QDVI 25 µg QD
Mean Change From Baseline (BL) in Clinic Visit Trough (Pre-bronchodilator and Pre-dose) FEV1, on Treatment Day 840.116 ± 0.00740.082 ± 0.0075
Statistical analysis
  • FF/VI 100/25 µg QD vs VI 25 µg QD · Mixed Models Analysis · p = 0.001 · Least squares mean difference: 0.034 · 95% CI 0.014 to 0.055Restricted maximum likelihood (REML)-based repeated measures approach (MMRM)
SecondaryPercentage of Rescue-free 24-hour Periods Over the Entire 12-week Treatment Period

Participants were given daily record cards for daily completion from BL (Week -1) through Week 12 (Visit 7) each morning and prior prior to taking study medication (i.e., single-blind and double-blind study medication), supplemental medication (albuterol \[salbutamol\] if received). Participants recorded number of occasions supplemental albuterol/salbutamol (MDI and/or nebules) or oxitropium bromide (applicable sites in Japan) used over the previous 24 hours and any medical problems that they had experienced and any medication used to treat these medical problems over the previous 24 hours. Rescue-free 24-hour periods are defined as the 24-hour periods in which the rescue medication (albuterol \[salbutamol\]) was not used. The percentage of 24-hour periods are summarized for the entire treatment period (12 weeks). Analysis was performed using an analysis of covariance (ANCOVA) model with covariates of treatment, reversibility status (stratum), baseline (week -1) and region.

Time frame:
BL (Week -1), Week 1 to Week 12
Reported as:
Least squares mean · Percentage of rescue-free periods
Percentage of Rescue-free 24-hour Periods Over the Entire 12-week Treatment Period
Percentage of rescue-free periodsFF/VI 100/25 µg QDVI 25 µg QD
Percentage of Rescue-free 24-hour Periods Over the Entire 12-week Treatment Period47.03 ± 1.07044.41 ± 1.069
Statistical analysis
  • FF/VI 100/25 µg QD vs VI 25 µg QD · ANCOVA · p = 0.084 · Least squares mean difference: 2.62 · 95% CI -0.35 to 5.59
SecondaryTime to First On-treatment Occurrence of Moderate or Severe COPD Exacerbation

Time to first on-treatment exacerbation was analysed using a Cox proportional hazards model with terms for treatment, reversibility status and percent predicted FEV1 at screening. Exacerbation of COPD is defined by a worsening of symptoms requiring additional treatment. Moderate COPD exacerbation is worsening symptoms of COPD that require treatment with antibiotics and/or systemic corticosteroids. Severe COPD exacerbation is worsening symptoms of COPD that require treatment with in-patient hospitalization. The number of participants with On-Treatment moderate or severe COPD exacerbations are presented.

Time frame:
From the start of double blind study medication until visit 7 (week 12)/Early withdrawal
Reported as:
Number · Participants
Time to First On-treatment Occurrence of Moderate or Severe COPD Exacerbation
ParticipantsFF/VI 100/25 µg QDVI 25 µg QD
Time to First On-treatment Occurrence of Moderate or Severe COPD Exacerbation69114
Statistical analysis
  • FF/VI 100/25 µg QD vs VI 25 µg QD · Regression, Cox · p = <0.001 (Nominal p-value) · Hazard ratio (hr): 0.58 · 95% CI 0.43 to 0.78

Adverse events

Collected over On-treatment serious adverse events (SAEs) and non-serious adverse events (AEs) were collected from the start of double-blind (DB) study treatment (Visit 2) through the follow up contact (up to 13 weeks).. Non-serious events are listed at a 3% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
FF/VI 100/25 µg QD—27/806 (3.3%)72/806 (8.9%)
VI 25 µg QD—35/814 (4.3%)64/814 (7.9%)
Most frequent serious events
Showing 10 of 55
Most frequent serious events
EventFF/VI 100/25 µg QDVI 25 µg QD
Any eventRespiratory, thoracic and mediastinal disorders10/80619/814
Chronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders10/80617/814
Any eventInfections and infestations6/8067/814
Any eventNeoplasms benign, malignant and unspecified (incl cysts and polyps)4/8064/814
PneumoniaInfections and infestations2/8064/814
Any eventCardiac disorders2/8063/814
Any eventInjury, poisoning and procedural complications1/8063/814
Any eventNervous system disorders2/8061/814
Any eventEye disorders2/8060/814
CataractEye disorders2/8060/814
Most frequent other events
Most frequent other events
EventFF/VI 100/25 µg QDVI 25 µg QD
NasopharyngitisInfections and infestations49/80648/814
HeadacheNervous system disorders29/80619/814

Baseline characteristics

Age, Continuous
Age, Continuous(Years)FF/VI 100/25 µg QDVI 25 µg QDTotal
Mean65.3 ± 8.5865.4 ± 9.0265.3 ± 8.80
Sex: Female, Male
Sex: Female, Male(Participants)FF/VI 100/25 µg QDVI 25 µg QDTotal
Female201189390
Male6056251230
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)FF/VI 100/25 µg QDVI 25 µg QDTotal
African American/African Heritage61016
Asian - East Asian Heritage7777154
Asian - Japanese Heritage185185370
White - White/Caucasian/European Heritage5385411079
Mixed Race011
08

Study locations

238 sites
  • GSK Investigational Site
    Riverside, California 92506, United States
  • GSK Investigational Site
    Sunset, Louisiana 70584, United States
  • GSK Investigational Site
    Saint Charles, Missouri 63301, United States
  • GSK Investigational Site
    Charlotte, North Carolina 28207, United States
  • GSK Investigational Site
    Wilmington, North Carolina 28401, United States
  • GSK Investigational Site
    Cincinnati, Ohio 45231, United States
  • GSK Investigational Site
    Medford, Oregon 97504, United States
  • GSK Investigational Site
    Erie, Pennsylvania 16508, United States
  • GSK Investigational Site
    Easley, South Carolina 29640, United States
  • GSK Investigational Site
    Gaffney, South Carolina 29340, United States
  • GSK Investigational Site
    Greenville, South Carolina 29615, United States
  • GSK Investigational Site
    Seneca, South Carolina 29678, United States
  • GSK Investigational Site
    Spartanburg, South Carolina 29303, United States
  • GSK Investigational Site
    Union, South Carolina 29379, United States
  • GSK Investigational Site
    Bristol, Tennessee 37620, United States
  • GSK Investigational Site
    Johnson City, Tennessee 37601, United States
  • GSK Investigational Site
    Morgantown, West Virginia 26505, United States
  • GSK Investigational Site
    Dimitrovgrad, 6400, Bulgaria
  • GSK Investigational Site
    Pleven, 5800, Bulgaria
  • GSK Investigational Site
    Plovdiv, 4000, Bulgaria
  • GSK Investigational Site
    Ruse, 7000, Bulgaria
  • GSK Investigational Site
    Sofia, 1202, Bulgaria
  • GSK Investigational Site
    Sofia, 1431, Bulgaria
  • GSK Investigational Site
    Varna, 9000, Bulgaria
  • GSK Investigational Site
    Vidin, 3700, Bulgaria
  • GSK Investigational Site
    Aschaffenburg, Bayern 63739, Germany
  • GSK Investigational Site
    Muenchen, Bayern 80339, Germany
  • GSK Investigational Site
    Muenchen, Bayern 80539, Germany
  • GSK Investigational Site
    Ruedersdorf, Brandenburg 15562, Germany
  • GSK Investigational Site
    Frankfurt, Hessen 60596, Germany
  • GSK Investigational Site
    Hannover, Niedersachsen 30159, Germany
  • GSK Investigational Site
    Hannover, Niedersachsen 30173, Germany
  • GSK Investigational Site
    Osnabrueck, Niedersachsen 49074, Germany
  • GSK Investigational Site
    Essen, Nordrhein-Westfalen 45359, Germany
  • GSK Investigational Site
    Goch, Nordrhein-Westfalen 47574, Germany
  • GSK Investigational Site
    Magdeburg, Sachsen-Anhalt 39112, Germany
  • GSK Investigational Site
    Delitzsch, Sachsen 04509, Germany
  • GSK Investigational Site
    Leipzg, Sachsen 04109, Germany
  • GSK Investigational Site
    Leipzig, Sachsen 04275, Germany
  • GSK Investigational Site
    Geesthacht, Schleswig-Holstein 21502, Germany
  • GSK Investigational Site
    Luebeck, Schleswig-Holstein 23552, Germany
  • GSK Investigational Site
    Berlin, 10367, Germany
  • GSK Investigational Site
    Berlin, 10717, Germany
  • GSK Investigational Site
    Berlin, 10787, Germany
  • GSK Investigational Site
    Berlin, 12203, Germany
  • GSK Investigational Site
    Aichi, 454-8502, Japan
  • GSK Investigational Site
    Aichi, 455-8510, Japan
  • GSK Investigational Site
    Aichi, 457-8511, Japan
  • GSK Investigational Site
    Aichi, 460-0001, Japan
  • GSK Investigational Site
    Aichi, 471-8513, Japan
  • GSK Investigational Site
    Aichi, 489-8642, Japan
  • GSK Investigational Site
    Chiba, 278-0004, Japan
  • GSK Investigational Site
    Chiba, 296-8602, Japan
  • GSK Investigational Site
    Ehime, 791-0281, Japan
  • GSK Investigational Site
    Fukuoka, 802-0052, Japan
  • GSK Investigational Site
    Fukuoka, 802-0083, Japan
  • GSK Investigational Site
    Fukuoka, 811-1394, Japan
  • GSK Investigational Site
    Fukuoka, 815-8588, Japan
  • GSK Investigational Site
    Fukuoka, 816-0813, Japan
  • GSK Investigational Site
    Fukuoka, 820-8505, Japan
  • GSK Investigational Site
    Fukuoka, 832-0059, Japan
  • GSK Investigational Site
    Gifu, 500-8523, Japan
  • GSK Investigational Site
    Gifu, 500-8717, Japan
  • GSK Investigational Site
    Gifu, 506-8550, Japan
  • GSK Investigational Site
    Gifu, 509-6134, Japan
  • GSK Investigational Site
    Gunma, 372-0831, Japan
  • GSK Investigational Site
    Hiroshima, 722-8503, Japan
  • GSK Investigational Site
    Hiroshima, 732-0052, Japan
  • GSK Investigational Site
    Hiroshima, 734-8530, Japan
  • GSK Investigational Site
    Hiroshima, 735-8585, Japan
  • GSK Investigational Site
    Hokkaido, 001-0901, Japan
  • GSK Investigational Site
    Hokkaido, 040-8611, Japan
  • GSK Investigational Site
    Hokkaido, 053-8506, Japan
  • GSK Investigational Site
    Hokkaido, 060-0033, Japan
  • GSK Investigational Site
    Hokkaido, 062-8618, Japan
  • GSK Investigational Site
    Hokkaido, 063-0005, Japan
  • GSK Investigational Site
    Hokkaido, 064-0801, Japan
  • GSK Investigational Site
    Hokkaido, 064-0915, Japan
  • GSK Investigational Site
    Hokkaido, 070-8644, Japan
  • GSK Investigational Site
    Hokkaido, 071-8132, Japan
  • GSK Investigational Site
    Hokkaido, 080-0013, Japan
  • GSK Investigational Site
    Hokkaido, 080-0805, Japan
  • GSK Investigational Site
    Hyogo, 650-0047, Japan
  • GSK Investigational Site
    Hyogo, 664-8540, Japan
  • GSK Investigational Site
    Hyogo, 672-8064, Japan
  • GSK Investigational Site
    Hyogo, 675-8611, Japan
  • GSK Investigational Site
    Hyogo, 678-0239, Japan
  • GSK Investigational Site
    Ibaraki, 310-0015, Japan
  • GSK Investigational Site
    Ibaraki, 317-0077, Japan
  • GSK Investigational Site
    Ibaraki, 319-1113, Japan
  • GSK Investigational Site
    Ishikawa, 920-8530, Japan
  • GSK Investigational Site
    Ishikawa, 920-8610, Japan
  • GSK Investigational Site
    Ishikawa, 920-8650, Japan
  • GSK Investigational Site
    Ishikawa, 921-8105, Japan
  • GSK Investigational Site
    Ishikawa, 923-8560, Japan
  • GSK Investigational Site
    Iwate, 024-8506, Japan
  • GSK Investigational Site
    Kagawa, 760-0018, Japan
  • GSK Investigational Site
    Kagawa, 760-8538, Japan
  • GSK Investigational Site
    Kagawa, 761-8073, Japan
  • GSK Investigational Site
    Kagawa, 762-8550, Japan

Showing the first 100 of 238 sites across 11 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Siler TM, Nagai A, Scott-Wilson CA, Midwinter DA, Crim C. A randomised, phase III trial of once-daily fluticasone furoate/vilanterol 100/25 mug versus once-daily vilanterol 25 mug to evaluate the contribution on lung function of fluticasone furoate in the combination in patients with COPD. Respir Med. 2017 Feb;123:8-17. doi: 10.1016/j.rmed.2016.12.001. Epub 2016 Dec 2. PubMed 28137501 ↗

Individual participant data

Plan to share: Yes — Patient-level data for this study will be made available through www.clinicalstudydatarequest.com following the timelines and process described on this site.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2014 to primary completion in Jul 2015, 15 months.

Results were first posted in Apr 2016, 9 months after primary completion.

Of 108 industry-sponsored phase 3 interventional studies under Pulmonary Disease, Chronic Obstructive, half reached primary completion within 20 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 36. This study's 15 months is below that.

Counting every sponsor, half of 141 studies reached it within 23 months; a quarter within 14 and three quarters within 44.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 3, 2014
First posted
Apr 7, 2014
StartActual
Apr 7, 2014
Primary completionActual
Jul 8, 2015
CompletionActual
Jul 8, 2015
Results first posted
Apr 13, 2016
Last update
Jan 24, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 24, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02105974
Lead sponsor
GlaxoSmithKline
Responsible party
Sponsor
First posted
Apr 7, 2014
Start date
Apr 7, 2014
Primary completion
Jul 8, 2015
Completion
Jul 8, 2015
Results posted
Apr 13, 2016
Last update
Jan 24, 2018

Study contacts

GSK Clinical Trials
study director · GlaxoSmithKline

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Fluticasone furoate · Vilanterol

Start the discussion